CoChat

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

Open access
Ulanet, Danielle B., Ludwig, Dale L., Kahn, C. Ronald, Hanahan, Douglas · 2010 · Proceedings of the National Academy of Sciences

The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.

Abstract

The type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinase is an important mediator of the protumorigenic effects of IGF-I/II, and inhibitors of IGF-1R signaling are currently being tested in clinical cancer trials aiming to assess the utility of this receptor as a therapeutic target. Despite mounting evidence that the highly homologous insulin receptor (IR) can also convey protumorigenic signals, its direct role in cancer progression has not been genetically defined in vivo, and it remains unclear whether such a role for IR signaling could compromise the efficacy of selective IGF-1R targeting strategies. A transgenic mouse model of pancreatic neuroendocrine carcinogenesis engages the IGF signaling pathway, as revealed by its dependence on IGF-II and by accelerated malignant progression upon IGF-1R overexpression. Surprisingly, preclinical trials with an inhibitory monoclonal antibody to IGF-1R did not significantly impact tumor growth, prompting us to investigate the involvement of IR. The levels of IR were found to be significantly up-regulated during multistep progression from hyperplastic lesions to islet tumors. Its functional involvement was revealed by genetic disruption of the IR gene in the oncogene-expressing pancreatic β cells, which resulted in reduced tumor burden accompanied by increased apoptosis. Notably, the IR knockout tumors now exhibited sensitivity to anti–IGF-1R therapy; similarly, high IR to IGF-1R ratios demonstrably conveyed resistance to IGF-1R inhibition in human breast cancer cells. The results predict that elevated IR signaling before and after treatment will respectively manifest intrinsic and adaptive resistance to anti–IGF-1R therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0914076107

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 2

  1. 10.1210/jcem.87.1.8142 · doi:10.1210/jcem.87.1.8142 · Paper page
  2. SM Shafie, FH Grantham, Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67, 51–56 (1981).

Cited by

See all 235

Metadata

Authors
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D.
Affiliations
  • University of California, San Francisco (US)
  • ImClone Systems, New York, NY 10014; and
  • Joslin Diabetes Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2010-05-10
Volume
107
Issue
24
Pages
10791-10798
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2005890897
Cited by
235
References
70
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 11 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 13 · 2018: 6 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 19 · 2013: 23 · 2012: 25
FWCI
21.00
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
  • A.P. Giannini Foundation
  • Joslin Diabetes Center
  • Giannini Foundation of Agricultural Economics
  • Fondation pour la Recherche Médicale
  • University of California, San Francisco
  • National Cancer Institute
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
insulin receptor, IGF-1 receptor, IGF signaling, tumor progression, pancreatic neuroendocrine carcinoma, pancreatic beta cells, monoclonal antibody therapy, breast cancer, apoptosis, insulin-like growth factor II, receptor tyrosine kinase signaling
MeSH terms
Animals, Antibodies, Monoclonal, Breast Neoplasms, Female, Humans, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Pancreatic Neoplasms, Receptor, Insulin, Signal Transduction, Receptor, IGF Type 1, Receptor, IGF Type 2, Mice, Knockout, Neuroendocrine Tumors, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. https://app.cochat.ai/papers/10.1073/pnas.0914076107
The paper
Ulanet, D. B., Ludwig, D. L., Kahn, C. R., & Hanahan, D. (2010). Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0914076107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.